Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Researchers Determine Predicting Factors Of Positive Lung Cancer Diagnoses In Chest Radiographs
A study published in the June 2009 issue of the Journal of Thoracic Oncology determined several predictors of a positive lung cancer diagnosis after having an abnormal chest x-ray. Dr. Martin Carl Tammemagi of Brock University in Ontario and his team of US researchers examined the chest radiographs of 12,314 individuals obtained through the National Cancer Institute"s Prostate Lung Colorectal Ovarian Cancer Screening Trial (PLCO). They found that older age, lower education levels and a longer smoking history were all associated with a "true positive" diagnosis for lung cancer in those individuals with an abnormal screening chest radiograph.
generic viagra online
APhA Publishes Reference On Drugs And Substances Of Abuse
The American Pharmacists Association (APhA) will publish in mid-July the second edition of Pagliaros" Comprehensive Guide to Drugs and Substances of Abuse. Written by veteran authors Louis A. Pagliaro and Ann Marie Pagliaro, the reference includes more than 100 monographs-11 of them new-dealing with each of the major drugs and substances of abuse used in North America, from acetone to zopiclone.
News of the day
UQ Ipswich Campus 10th Anniversary And Launch Of Teaching Of Medicine, Australia
An event to mark the celebrate the 10th anniversary of the UQ Ipswich Campus and the launch of UQ"s teaching of Medicine at UQ Ipswich will be held today, Friday, July 24, 2009.
Endocrinology

Dr. David Fischell To Speak At The EuroPCR Conference In Barcelona On The Detection Of Plaque Rupture With The AngelMed Guardian System.

Angel Medical Systems has announced that Dr. David Fischell, Chief Executive Officer, will be the first featured speaker at the upcoming Out-of-the-box "Session Innovation@EuroPCR09" on May 19 in Barcelona, Spain. EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Dr. Fischell"s presentation will highlight data from recent human clinical studies showing the AngelMed Guardian System"s ability to detect vulnerable plaque rupture. "When someone has a heart attack, it is typically the result of a blood clot closing one of the three major coronary arteries. When this happens, there is a shift in the ST segment of the heart signal caused by the electrical difference between the portion of the heart muscle fed by the closed artery and the rest of the heart that is still receiving oxygen," says Dr. Fischell. The Guardian System is designed to internally monitor ECG signals in real time, 24-hours-a-day, to detect these ST shifts resulting from coronary occlusions. The System is comprised of an internal implantable device about the size of a pacemaker with a single pacemaker lead into the heart, an external pager-like alerting device, and a programmer that lets physicians read out the heart signals. Early clinical cases have shown the Guardian System"s ability to detect plaque ruptures in patients and warn them to seek immediate medical attention. "Experimental and clinical studies have shown that most of the damage to the heart occurs during the first two hours after coronary occlusion," adds Dr. Fischell. "This device has the potential to warn patients hours--perhaps even days--before a heart attack occurs." The Guardian System is currently available commercially in Brazil, and is in the ALERTS Phase II Pivotal trial in clinical sites across the United States. The first implants in the ALERTS trial took place in December, 2008 with sites across more than 10 states now enrolling patients in the study. Angel Medical is currently ISO 13485 certified and is working with a notified body to gain CE mark approval. Angel Medical Systems


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009